Concurrent Investment Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Concurrent Investment Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.4M	Sell	30,377 -11,522	-27%	-$2.31M	0.04%	413
2026 Q2	$7.97M	Buy	41,899 +1,567	+4%	+$269K	0.07%	319
2026 Q1	$6.81M	Buy	40,332 +4,643	+13%	+$794K	0.07%	287
2025 Q4	$6.02M	Buy	35,689 +31,766	+810%	+$5.16M	0.07%	285
2025 Q3	$566K	Sell	3,923 -77	-2%	-$10.5K	0.01%	859
2025 Q2	$506K	Sell	4,000 -523	-12%	-$64.2K	0.01%	842
2025 Q1	$579K	Buy	4,523 +375	+9%	+$50.8K	0.01%	705
2024 Q4	$548K	Buy	4,148 +436	+12%	+$61.3K	0.01%	647
2024 Q3	$541K	Buy	3,712 +123	+3%	+$17.8K	0.02%	600
2024 Q2	$493K	Buy	3,589 +630	+21%	+$84.1K	0.02%	588
2024 Q1	$406K	Sell	2,959 -66	-2%	-$9.01K	0.02%	605
2023 Q4	$411K	Buy	+3,025	New	+$369K	0.02%	543

Other funds holding IBB

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

MWM

MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return

FNFDCM

Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.18B AUM 27.44% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return

Equitable Trust Nashville, Tennessee $2.38B AUM 22.38% 1-Year Est. Return

Concurrent Investment Advisors's IBB Position: Q3 2026 in Review

Concurrent Investment Advisors reduced its iShares Biotechnology ETF (IBB) stake by 27% in Q3 2026, selling an estimated $2.31M and leaving 30,377 shares worth $6.4M. The position accounts for 0.04% of the portfolio, ranked #413.

Concurrent Investment Advisors first reported a position in IBB in Q4 2023 and has held it in 12 quarters since. The position peaked at $7.97M in Q2 2026. 156 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

Concurrent Investment Advisors held 30,377 shares of iShares Biotechnology ETF worth $6.4M as of Q3 2026.
Concurrent Investment Advisors sold 11,522 iShares Biotechnology ETF shares in Q3 2026, an estimated $2.31M.
iShares Biotechnology ETF made up 0.04% of Concurrent Investment Advisors's portfolio in Q3 2026, its #413 holding.
Concurrent Investment Advisors first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 12 quarters since.
Concurrent Investment Advisors's iShares Biotechnology ETF position peaked at $7.97M in Q2 2026.
156 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Concurrent Investment Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.